The Company Announces Pricing of Initial Public Offering
BRUSSELS, Belgium, November 7, 2019 — CENTOGENE has issued a press release today announcing that its shares are beginning to trade on the NASDAQ stock exchange with immediate effect under the ticker symbol ‘CNTG’.
The Initial Public Offering of the Company shares represents a major milestone on CENTOGENE development and would certainly serve to solidify its presence as a major specialized diagnostics player, key partner to the pharmaceutical industry and reliable provider of services to both patients and physicians.
Eric Souêtre, Careventures Partner commented “Careventures is committed to continue supporting the Company and will remain a major and loyal shareholder and Supervisory Board Member. We believe that the CENTOGENE offering in the rare disease diagnostic market is unique and that the new public nature of the Company will allow to boost its presence worldwide”.
More information on the IPO of CENTOGENE shares can be found here.